Impact of glucocorticoids on the therapeutic efficacy of denosumab against osteoporosis in patients with rheumatoid arthritis.

ABSTRACT:

Background

Rheumatoid arthritis (RA) and prolonged high-dose glucocorticoid (GC) treatment are established risk factors for osteoporosis.

Objectives

In this study, we aimed to evaluate the therapeutic efficacy of denosumab according to the GC dose considered to increase the risk of glucocorticoid-induced osteoporosis (GIOP) in patients with RA.

Design

A retrospective analysis of collected data on RA patients with osteoporosis starting denosumab.

Methods

We included 418 patients with RA who were started on denosumab therapy and categorized them into those with and without GC intake ⩾2.5 mg/day for >3 months. The T-score and areal bone mineral density (aBMD) at the lumbar spine, total hip, and femur neck, as well as serum bone turnover markers, were measur

SUBMITTER: Yang J 

PROVIDER: S-EPMC11775979 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature